Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Is the current diagnostic algorithm reliable for selecting cases for EGFR- and KRAS-mutation analysis in lung cancer?

Lung cancer (Amsterdam, Netherlands) - 1 Jul 2015

Vincenten Julien P L, Smit Egbert F, Grünberg Katrien, Postmus Pieter E, Snijders Peter J F, Witte Birgit I, Heideman Daniëlle A M, Thunnissen Erik

Abstract excerpt

OBJECTIVES: Adenocarcinoma (ADC) of the lung may harbor EGFR- or KRAS-mutations, which are relevant for treatment decisions. There is no consensus on the percentages of EGFR- and KRAS-mutations that are allowed to be missed by a diagnostic algorithm, although a percentage of less than 1% for EGFR-mutations has been suggested. The current guidelines do not advise to perform EGFR-mutation analysis in unequivocal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Carcinoma, Squamous Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diagnostic Errors

Share to ErbB Receptors

Share to Patient Selection

Share to Practice Guidelines as Topic

Share to Proto-Oncogene Proteins p21(ras)

Share to Tumor Suppressor Proteins

Source

Identifiers

PMID: 25982011
DOI: 10.1016/j.lungcan.2015.04.005

Genes

EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Is the current diagnostic algorithm reliable for selecting cases for EGFR- and KRAS-mutation analysis in lung cancer?PMID 25982011Read ↗

What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements.Semantic proximity Read ↗

Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing.Semantic proximity Read ↗

KRAS mutation: should we test for it, and does it matter?Semantic proximity Read ↗

Establishing an EGFR mutation screening service for non-small cell lung cancer – Sample quality criteria and candidate histological predictorsSemantic proximity Read ↗

EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype.Semantic proximity Read ↗

Clinical relevance of the new IASLC/ERS/ATS adenocarcinoma classification.Semantic proximity Read ↗

Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas.Semantic proximity Read ↗

Correlation between molecular analysis, diagnosis according to the 2015 WHO classification of unresected lung tumours and TTF1 expression in small biopsies and cytology specimens from 344 non-small cell lung carcinoma patients.Semantic proximity Read ↗

EGFR and KRAS mutational profiling in fresh non-small cell lung cancer (NSCLC) cells.Semantic proximity Read ↗

Reliability of EGFR and KRAS mutation analysis on fine-needle aspiration washing in non-small cell lung cancer.Semantic proximity Read ↗

Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.Semantic proximity Read ↗

Should EGFR mutations be tested in advanced lung squamous cell carcinomas to guide frontline treatment?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.